Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
US Department of Justice
Fuji
Healthtrust
Deloitte
AstraZeneca
Baxter
Citi
McKesson

Generated: November 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022307

« Back to Dashboard

NDA 022307 describes EFFIENT, which is a drug marketed by Eli Lilly And Co and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the EFFIENT profile page.

The generic ingredient in EFFIENT is prasugrel hydrochloride. There are nineteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the prasugrel hydrochloride profile page.
Summary for 022307
Tradename:EFFIENT
Applicant:Eli Lilly And Co
Ingredient:prasugrel hydrochloride
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 022307
Mechanism of ActionP2Y12 Receptor Antagonists
Physiological EffectDecreased Platelet Aggregation
Medical Subject Heading (MeSH) Categories for 022307
Suppliers and Packaging for NDA: 022307
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EFFIENT prasugrel hydrochloride TABLET;ORAL 022307 NDA Eli Lilly and Company 0002-5121 0002-5121-30 30 TABLET, FILM COATED in 1 BOTTLE (0002-5121-30)
EFFIENT prasugrel hydrochloride TABLET;ORAL 022307 NDA Eli Lilly and Company 0002-5121 0002-5121-52 24 BLISTER PACK in 1 CARTON (0002-5121-52) > 1 TABLET, FILM COATED in 1 BLISTER PACK (0002-5121-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 5MG BASE
Approval Date:Jul 10, 2009TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Jan 12, 2020
Regulatory Exclusivity Use:PEDIATRIC EXCLUSIVITY
Regulatory Exclusivity Expiration:Jul 12, 2019
Regulatory Exclusivity Use:UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, 'A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE'
Patent:➤ Try a Free TrialPatent Expiration:Jul 2, 2023Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 022307

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-001 Jul 10, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Eli Lilly And Co EFFIENT prasugrel hydrochloride TABLET;ORAL 022307-002 Jul 10, 2009 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
US Department of Justice
Colorcon
Merck
Citi
Argus Health
Deloitte
Mallinckrodt
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.